Match!
Geoff Cohen
University of Edinburgh
38Publications
14H-index
2,640Citations
Publications 38
Newest
#1William Whiteley (Edin.: University of Edinburgh)H-Index: 30
#2Jonathan Emberson (Clinical Trial Service Unit)H-Index: 47
Last.Colin Baigent (Clinical Trial Service Unit)H-Index: 66
view all 28 authors...
Summary Background Randomised trials have shown that alteplase improves the odds of a good outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to determine the proportional and absolute effects of alteplase on the risks of intracerebral haemorrhage, mortality, and functional impairment in different types of patients. Methods We used individual patient data from the Stroke Thrombolysis Trialists' (STT) me...
53 CitationsSource
#1Peter Sandercock (Edin.: University of Edinburgh)H-Index: 82
#2Joanna M. Wardlaw (Edin.: University of Edinburgh)H-Index: 89
Last.Geoff Cohen (Edin.: University of Edinburgh)H-Index: 14
view all 5 authors...
2 CitationsSource
#1Peter SandercockH-Index: 82
#2Joanna M. WardlawH-Index: 89
Last.William WhiteleyH-Index: 30
view all 5 authors...
1 CitationsSource
#1Grant Mair (Edin.: University of Edinburgh)H-Index: 11
#2Rüdiger von Kummer (TUD: Dresden University of Technology)H-Index: 41
Last.Joanna M. Wardlaw (Edin.: University of Edinburgh)H-Index: 89
view all 14 authors...
OBJECTIVE: To investigate whether the location and extent of the CT hyperdense artery sign (HAS) at presentation affects response to IV alteplase in the randomized controlled Third International Stroke Trial (IST-3). METHODS: All prerandomization and follow-up (24-48 hours) CT brain scans in IST-3 were assessed for HAS presence, location, and extent by masked raters. We assessed whether HAS grew, persisted, shrank, or disappeared at follow-up, the association with 6-month functional outcome, and...
11 CitationsSource
#1Grant Mair (Edin.: University of Edinburgh)H-Index: 11
#2Trevor K. CarpenterH-Index: 13
Last.Joanna M. Wardlaw (Edin.: University of Edinburgh)H-Index: 89
view all 6 authors...
Source
#1Eivind Berge (University of Oslo)H-Index: 27
#2Geoff Cohen (Edin.: University of Edinburgh)H-Index: 14
Last.William WhiteleyH-Index: 30
view all 7 authors...
Background and Purpose—In patients with acute ischemic stroke, a high blood pressure or a highly variable blood pressure is a common reason for withholding thrombolytic treatment, but guidelines recommend a conservative approach to active blood pressure lowering in this setting. We have performed exploratory analyses to study the clinical effects of blood pressure and early blood pressure–lowering treatment in patients included in a randomized-controlled trial of thrombolytic treatment for acute...
24 CitationsSource
#1Pooja KhatriH-Index: 44
#2Darren TayamaH-Index: 6
Last.Peter Sandercock (Edin.: University of Edinburgh)H-Index: 82
view all 8 authors...
Background and Purpose—Randomized trial evidence on the risk/benefit ratio of thrombolysis for mild stroke is limited. We sought to determine the efficacy of intravenous recombinant tissue-type plasminogen activator (IV r-tPA) in a subset of patients with mild deficit in the third International Stroke Trial (IST-3). Methods—IST-3 compared IV r-tPA with control within 6 hours of onset in patients for whom IV r-tPA was considered promising but unproven. Analysis was restricted to subjects randomiz...
24 CitationsSource
#1Joanna M. Wardlaw (Edin.: University of Edinburgh)H-Index: 89
#2Rüdiger von KummerH-Index: 41
Last.Peter Sandercock (Edin.: University of Edinburgh)H-Index: 82
view all 11 authors...
RATIONALE: Intravenous thrombolysis with recombinant tissue Plasminogen Activator improves outcomes in patients treated early after stroke but at the risk of causing intracranial hemorrhage. Restricting recombinant tissue Plasminogen Activator use to patients with evidence of still salvageable tissue, or with definite arterial occlusion, might help reduce risk, increase benefit and identify patients for treatment at late time windows. AIMS: To determine if perfusion or angiographic imaging with ...
18 CitationsSource
#1Joanna M. WardlawH-Index: 89
#2Peter Sandercock (Edin.: University of Edinburgh)H-Index: 82
Last.Eleni Sakka (Edin.: University of Edinburgh)H-Index: 12
view all 17 authors...
Background: Brain scans are essential to exclude haemorrhage in patients with suspected acute ischaemic stroke before treatment with alteplase. However, patients with early ischaemic signs could be at increased risk of haemorrhage after alteplase treatment, and little information is available about whether pre-existing structural signs, which are common in older patients, affect response to alteplase. We aimed to investigate the association between imaging signs on brain CT and outcomes after al...
64 CitationsSource
#1Richard Issacson (USYD: University of Sydney)H-Index: 41
#2Joanna M. Wardlaw (Edin.: University of Edinburgh)H-Index: 89
Last.Eva IsaaksonH-Index: 1
view all 81 authors...
Background and Purpose—Our aim was to identify whether particular subgroups of patients had an unacceptably high risk of symptomatic intracranial hemorrhage or low chance of benefit when treated with alteplase (recombinant tissue-type plasminogen activator). Methods—Third International Stroke Trial was an international randomized trial of the intravenous (IV) recombinant plasminogen activator alteplase (0.9 mg/kg) versus control in 3035 (1515 versus 1520) patients. We analyzed the effect of reco...
37 CitationsSource
1234